MED vs SCI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

MED

32.2
AI Score
VS
SCI Wins

SCI

58.9
AI Score

Investment Advisor Scores

MED

32score
Recommendation
SELL

SCI

59score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED SCI Winner
Revenue 224.48M 3.31B SCI
Net Income -22.73M 401.91M SCI
Gross Margin 69.1% 25.2% MED
Net Margin -10.1% 12.2% SCI
Operating Income -26.98M 728.29M SCI
ROE -12.6% 25.5% SCI
ROA -9.5% 2.1% SCI
Total Assets 239.76M 19.09B SCI
Cash 58.37M 172.65M SCI
Current Ratio 4.82 0.40 MED

Relative Price Performance (Last 90 Days)

MED 1M: +8.5% · 3M: +12.4% SCI 1M: -5.6% · 3M: -11.0%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 57

RSI (14): 56.9 · Price: $12.86

SCI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 42

RSI (14): 42.2 · Price: $74.97

Fundamentals Snapshot

Metric MED SCI
Market Cap — —
Forward P/E -321.5 17.3
Trailing P/E — 18.8
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin 0.7% 0.3%
Operating Margin -0.1% 0.2%
EPS -3.70 4.02
Dividend Yield — 0.02%

Frequently Asked Questions

Based on our detailed analysis, SCI is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.